A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area

• Status: Completed
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universitaire Ziekenhuizen Leuven
• Collaborators: Institutul Clinic Fundeni; Institutul Clinic Fundeni Bucharest
• Treatments: Posaconazole

Criteria

Inclusion Criteria:

• 2-13 years of age

• hematological malignancy

• need for antifungal prophylaxis because of neutropenia caused by chemotherapy and/or hematopoietic stem cell transplantation.

Exclusion Criteria:

• <2 years of age

• > 13 years of age